September 12, 2023
Today at #EANM23 in Vienna, Dr. Umberto Battisti presented our data and findings as an EANM-highlighted lecture. We are grateful for the opportunity to show our data to the scientific community dedicated to this field.
Please reach out if you want to hear more about our platform technology.
September 9, 2023
Highlight at EANM 23
Thank you European Association of Nuclear Medicine (EANM) for choosing our talk as a highlight session for this year.
You are invited to the Tuesday morning session, where Dr. Umberto Maria Battisti will present our universal labeling platform and its application to develop radiopharmaceuticals labeled with 18F and 211At.
The talk will take place on Tuesday, September 12th, from 09:45 to 11:15 at the M2M Track.
We hope to see you there.
September 7, 2023
We are pleased to announce that Dr. Umberto Maria Battisti, the COO and co-founder of TetraKit Technologies, will be speaking at the European Association of Nuclear Medicine (EANM) 23. During the speech, he will highlight the inventive application of our platform in creating next-generation theranostics with the use of 211At.
We are excited to have you join us on this special occasion.
August 11, 2023
TetraKit Technologies is pleased to announce our participation in the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna from September 09-13, 2023.
We are particularly excited to highlight that Dr. Umberto Battisti will deliver a talk on how our platform can be used to synthesize theranostics using 211At.
*Please note that Dr. Battisti’s presentation is scheduled for the morning of September 12th.
For appointments and discussions, please connect with our team members:
Dr. Umberto Battisti, Dr. Andreas Jensen, Dr. Matthias Herth, and Dr. Christian Poulie.
Alternatively, you can reach us via email at email@example.com.
We look forward to engaging with you in Vienna 🇦🇹
July 26, 2023
Exciting Opportunity! TetraKit Technologies is currently seeking a Medicinal Chemist/Radiopharmaceutical Specialist.
Let’s shape the future together!
medicinalchemistry #radiopharmaceuticals #wearehiring
May 20, 2023
We are delighted to announce that our distinguished Chief Scientific Officer, Dr. Matthias Herth, will attend the 25th International Society for Radiopharmaceutical Sciences (ISRS) conference in beautiful Hawaii.
The ISRS conference, renowned for fostering innovation and collaboration, is an ideal platform for presenting our pioneering work and engaging with fellow industry thought leaders. We eagerly anticipate the exchange of ideas that will occur and the partnerships that could potentially evolve from this assembly of bright minds.
Here’s to pushing boundaries toward a brighter, healthier future.
May 10, 2023
Our COO, Umberto Maria Battisti, will attend the 23rd annual @BioEquity conference in Dublin, Ireland! Umberto’s participation in BioEquity Europe 2023 highlights our commitment to innovation and growth. During the conference, he will seek new partnerships, discuss the latest advancements in biotechnology, and share insights into our company’s strategy for sustained success. We invite you to celebrate Umberto’s journey to Dublin with us, and stay tuned for updates on his experience at this prestigious event. Together, let’s pave the way for a brighter future in biotech!
May 8, 2023
We’re excited to announce that TetraKit will attend the 2nd Annual Global Meeting COST NOAR Astatine in Coimbra, Portugal, from May 9-11, 2023! This event will bring together academics and industry experts to discuss the latest developments in targeted alpha therapy using astatine-211. Our CEO, Andreas Ingemann Jensen, and CSO, Matthias Herth, represent TetraKit at this global conference. They look forward to engaging in productive conversations, exchanging ideas, and learning from the invited speakers. We’re thrilled to network with fellow professionals and contribute to the progress in this innovative field.
April 9, 2023
Hoppin’ into an enjoyable and happy Easter 🐣 🐇
March 16, 2023
As one of the major events in molecular imaging, EMIM brings together experts from various disciplines to share their latest research findings and network with peers.
We are proud to have Dr. Herth represent Tetrakit Technologies at this important event.
March 16, 2023
🎉 Exciting News Alert! 🎉
We are proud to announce that Tetrakit Technologies has officially joined the prestigious Venture House at BioInnovation Institute! 🏢🔬
This is a significant milestone for our team, and we couldn’t be happier to be part of such an inspiring ecosystem of innovative biotech and life sciences startups. 🌐
A big thank you to the entire Tetrakit team for their relentless passion, dedication, and hard work that has led us to this incredible opportunity. 🙌
We also want to express our gratitude to the BioInnovation Institute for recognizing our potential and providing us with this exceptional platform to grow, collaborate, and make a lasting impact in the world of biotechnology. 🧪💡
As we embark on this new journey, we’re more motivated than ever to push boundaries, develop groundbreaking solutions, and, ultimately, improve the lives of millions around the globe. 🌍💊
Stay tuned for more updates on our progress and the exciting developments to come! 🚀
March 15, 2023
A warm welcome to our newest team member, Nadia. With experience in organic and biomolecular chemistry, Nadia brings knowledge and expertise to our team. Nadia is part of our collaboration with the University of Copenhagen for the development of theranostics targeting the neuropeptide Y1 receptor.
- Nadia, can you tell us briefly about your background?
Sure, I graduated from the Technical University of Denmark with an MSc in Applied Chemistry. Through my previous project, I obtained key competencies in biomolecular design, synthesis, characterization, and planning and running bioassays. I am highly motivated to work with biomolecular chemistry because of the urgent need and high applicability in modern diagnostics and medicine.
- What attracted you to our team, and what excites you most about your new role?
TetraKit develops unique radiolabeling based on click chemistry to facilitate cancer diagnosis and therapy. I am happy to be part of the TetraKit team during my Ph.D. fellowship, as I see my research profile fitting within these objectives. Especially, I am excited to be working with a talented team and contributing to further developing the TetraKit solutions. In my new role, I look forward to expanding my expertise working with radiopharmaceutical chemistry, which will allow me to utilize my skills in the development of theranostics.
- What are your long-term career goals?
As a Ph.D. fellow, I wish to expand my scientific profile and conduct high-level research. This role is ideal for me to do so. The skills and experience I gain in this role will give me a unique set of professional skills of high value for my future carrier.
We are thrilled to have Nadia on board and look forward to this cooperation. Welcome to the team, Nadia!
March 2, 2023
1st anniversary in the BII community
We are thrilled to announce that we are celebrating our 1st anniversary as a Venture Lab startup at BioInnovation Institute! It has been an incredible journey filled with challenges and triumphs, and we are grateful for the opportunity to share it with you all.
Looking back on the past year, we are amazed at how much we have accomplished. We have grown our team and forged new partnerships. We have also faced obstacles and made mistakes but have learned from them and emerged stronger.
Our team has worked tirelessly to create a solution that finds and destroys cancer tumors, and we are proud of what we have accomplished so far.
Our click-chemistry-based radiochemical platform, TetraKit, has the potential to make a real difference in the world, and we are excited about the possibilities it holds for the future. We look forward to refining and improving our product and working with partners who share our vision and values.
Thank you all for being a part of our transformative journey. We look forward to continuing to work together and making great things happen!
February 24, 2023
Tetrakit Technologies will be heading to Cape Town, South Africa, for TAT-12, where we will partake in a cutting-edge symposium featuring the latest advancements in targeted alpha therapy. This is an excellent opportunity to network with colleagues from around the globe. Feel free to reach out if you would like to meet us. Contact Andreas for more information or to schedule an appointment.
#southafrica #opportunity #network #targetedalphatherapy
February 13, 2023
The premier international gathering place in Europe for financial power players and biopharma executives to connect with burgeoning biotechnology companies.
January 20, 2023
BioSeed 2023 in London
Our CEO, Andreas Jensen, will present at BioSeed in London, UK. Please reach us if you are interested in learning more about our universal labelling platform for theranostics and how it can be applied in your drug development programs. Schedule a meeting with Andreas Ingemann Jensen, PhD Pharm, by contacting him directly.
See you on Monday!
December 31, 2022
Happy New Year 2023 💫
As we start a new year, it is a time for reflection and setting new goals. The new year is a chance to leave the past behind and look toward the future with hope and determination. It is an opportunity to start fresh and make positive changes in our lives. I hope that this new year brings you joy, health, and prosperity and that you are able to achieve all that you set out to do. Happy New Year!
December 9, 2022
We are happy to announce a Ph.D. fellowship collaboration with Dept. of Drug Design and Pharmacology (ILF), University of Copenhagen. Welcome to apply via the Faculty of Health and Medical Sciences, https://healthsciences.ku.dk/
#university #collaboration #health #phd
November 29, 2022
This year’s Nobel Prize in chemistry prompted the Danish Newspaper Radiograf Rådet to publish a story about the academic research of Dr. Matthias Herth, our very own CSO, using click chemistry. Check it out (in Danish only) 😊 https://lnkd.in/eddXebf2
#clickchemistry #positronemissiontomography #radiotherapy
November 22, 2022
We are pleased to announce an agreement with Rigshospitalet (The National Hospital of Denmark), Department of Clinical Physiology, Nuclear Medicine & PET to supply us with astatine-211 (At-211) for our development programs.
#hospital #medicine #TAT #alphatherapy #alphaisotopes
October 10, 2022
TRIMT and TETRAKIT
About TRIMT TRIMT GmbH is a clinical-stage company developing novel radiopharmaceuticals to diagnose and treat life-threatening diseases. The company was founded in early 2021 in Radeberg near Dresden (Germany). TRIMT holds a worldwide exclusive license for various new radioligands based on technologies from the Technical University of Munich.
October 6, 2022
As an international expert in click chemistry, Dr. Matthias Herth, our CSO at TetraKit Technologies, was asked by ZEIT ONLINE to comment on this year’s Nobel Prize winners in Chemistry.
#future #technology #chemistry #drugdevelopment
Read more about this fascinating new technology with incredible potential for future drug development:
October 6, 2022
Congrats to the Nobel Prize winners, Carolyn R. Bertozzi, Morten Meldal, and K. Barry Sharpless “for developing click chemistry and bioorthogonal chemistry.” TetraKit Technologies concurs with this outstanding decision of the Nobel Prize Committee. Click chemistry is also the core of our TetraKit platform, with broad application in pretargeting or drug delivery strategies. The Noble Prize homepage announced, “It just says click – and the molecules are coupled together.”
We are looking forward to a bright future of click and bioorthogonal chemistry. #future#chemistry#nobelprize
Read more about this year’s Nobel Laureates in Chemistry: